摘要
目的：了解ｒａｓ和ｅｒｂＢ２基因在肺癌中表达的临床意义。方法：采用免疫组化技术研究了ｒａｓｐ２１和ｅｒｂＢ２ｐ１８５在４０例肺癌（腺癌１９例，鳞癌１８例，腺鳞癌１例，小细胞肺癌２例）中的表达，并将肺癌按临床病理特征分组进行对比分析。结果：①在非小细胞肺癌（ＮＳＣＬＣ）中，ｐ２１的阳性率为６１％，ｐ１８５的阳性率为４２％，２例小细胞肺癌（ＳＣＬＣ）均无ｐ２１和ｐ１８５的表达。②ｐ１８５在肺腺癌中的表达明显高于鳞癌（Ｐ＜０．０５）。③在ＮＳＣＬＣ中，ｐ２１在Ⅰ～Ⅱ期中的阳性率为２５％，Ⅲａ～Ⅲｂ期中的阳性率为７７％，两者有非常显著的差异（Ｐ＜０．０１）。④ｐ２１和ｐ１８５阳性的ＳＮＣＬＣ患者，其淋巴结转移发生早，速度快（Ｐ＜０．０５）。⑤ｐ１８５在ＳＮＣＬＣ中的表达存在性别差异，女性明显高于男性（Ｐ＜０．０１）。结论：ｒａｓ和ｅｒｂＢ在ＮＳＣＬＣ中的表达具有重要的临床意义。
Purpose: To assess the clinical significance of the expression of ras and erbB2 in human lung carcinomas; Method: 40 Tumors from patients with adenocarcinoma (19), squamous cell carcinoma (18), adenosquamous carcinoma (1) and small cell carcinoma (2) of the lung were examined for ras p21 and erbB p185 using immunohistochemical methods. They were divided into groups, contrasted and analysed according their clinicopathologic characteristics. Results: (1)Overexpression of ras p21 erbB p185 were observed in 61% and 42% respectively of non-small cell lung cancer (NSCLC), no positive reaction was found in the two cases of small cell lung cancer (SCLC); (2)The positive rate of p185 in adenocarcinomas showed higher frequencly than that in squamous cell carcinomas (P<0.05); (3)In NSCLC, the positive rate of p21 was 25% in stage Ⅰ～Ⅱ, 77% in stage Ⅲa-Ⅲb, respectively, the difference was significant (P<0.01); (4)In the patients with SNCLC which express p21 and p185, lymph node metastasis was earlier and more rapid (P<0.05); (5)There was sexual difference in expression of p185, incidence of p185 positive staining in females was much higher than that in males (P<0.01). Conclusion: Our findings suggest that the expression of ras and erbB2 in NSCLC is of more clinical signifcanfce.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1998年第2期99-101,F003,共4页
Chinese Journal of Cancer
